These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 16426900)

  • 21. The challenges of HIV vaccine development and testing.
    Burgers WA; Williamson C
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 23. HIV vaccine efficacy trials: A brief history, and options for going forward.
    McKinnon LR; Card CM;
    AIDS Rev; 2010; 12(4):209-17. PubMed ID: 21179185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV immunology: what lessons can we learn from recent vaccine trials?
    Kelleher P
    J HIV Ther; 2010 Mar; 15(1):2-5. PubMed ID: 21180231
    [No Abstract]   [Full Text] [Related]  

  • 25. [Ethical elements in the development of vaccines against HIV/AIDS].
    Molina CN
    Sidahora; 2001 Oct; ():14-6. PubMed ID: 11776246
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenicity assay validation for an HIV vaccine trial: high IFNγ+/IL-2+ CD8+ T cells background in healthy Thais.
    Sirivichayakul S; Thantiworasit P; Chatkulkawin P; Buranapraditkun S; Munier ML; Kelleher AD; Ruxrungtham K
    Vaccine; 2011 Aug; 29(35):6002-7. PubMed ID: 21718737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
    Sheppard N; Sattentau Q
    Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
    Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
    J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV vaccine research in Thailand: lessons learned.
    Pitisuttithum P
    Expert Rev Vaccines; 2008 Apr; 7(3):311-7. PubMed ID: 18393601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
    Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
    Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [BCG vaccination and development of an innovative vaccine for preventing vertical HIV transmission in Africa].
    Pontrelli G; Colizzi V
    Ig Sanita Pubbl; 2006; 62(2):189-99. PubMed ID: 17206189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversial HIV vaccine enters phase III trials amid skepticism.
    AIDS Alert; 1998 Dec; 13(12):133-4, 136. PubMed ID: 11366059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV/AIDS. Hedged bet: an unusual AIDS vaccine trial.
    Cohen J
    Science; 2005 Aug; 309(5737):1003. PubMed ID: 16099960
    [No Abstract]   [Full Text] [Related]  

  • 36. [The quest for an HIV vaccine].
    Girard MP
    Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remune trial will stop; new trials planned.
    James JS
    AIDS Treat News; 1999 May; (No 319):1-2. PubMed ID: 11366461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV vaccines 1983-2003.
    McMichael AJ; Hanke T
    Nat Med; 2003 Jul; 9(7):874-80. PubMed ID: 12835708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.
    Maek-A-Nantawat W; Pitisuttithum P; Phonrat B; Bussaratid V; Naksrisook S; Peonim W; Thantamnu N; Muanaum R
    J Med Assoc Thai; 2003 Apr; 86(4):299-307. PubMed ID: 12757073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.